Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Juni 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...
31. Mai 2023 08:04 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
10. Mai 2023 13:00 ET | Quelle: DelveInsight Business Research LLP

Checkpoint Inhibitors Clinical Trial Pipeline Appears Robust with 180+ Key Pharma Players Actively Working in the Space, Estimates DelveInsight

New York, USA, May 10, 2023 (GLOBE NEWSWIRE) -- Checkpoint Inhibitors Clinical Trial Pipeline Appears Robust with 180+ Key Pharma Players Actively Working in the Space, Estimates DelveInsight The...
08. Mai 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
08. Mai 2023 06:48 ET | Quelle: Research and Markets

Global Checkpoint Inhibitors Competitive Landscape Report 2023: Comprehensive Insights About 180+ Companies and 250+ Drug Profiles

Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "Checkpoint inhibitors -...
19. April 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
17. April 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Appoints Andrew Singer to its Board of Directors

Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategyFormer EVP and CFO of Epizyme and Senior Biotech Investment Banker at...
04. April 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in...
03. April 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical...
20. März 2023 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...

Vorherige Seite

Nächste Seite